rituxumab 100mg, 500mg solution for infusion (MabThera®)
Roche Products Ltd

8 February 2019

**ADVICE:** in the absence of a submission from the holder of the marketing authorisation rituxumab (MabThera®) is not recommended for use within NHSScotland.

**Indication under review:** in combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).

The holder of the marketing authorisation has not made a submission to SMC regarding this product as maintenance treatment. As a result we cannot recommend its use within NHSScotland.

SMC has previously accepted rituximab for restricted use in combination with glucocorticoids, for the induction of remission in adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA) (SMC 894/13). This advice remains valid.

**Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

**Chairman**
Scottish Medicines Consortium

Published 11 March 2019